Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare progression free survival for SU011248 [sutent
(sunitinib malate)] versus standard of care therapy in patients with previously treated,
advanced, triple receptor negative (ER, PR, HER2) locally recurrent or metastatic breast
cancer.